<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00202397</url>
  </required_header>
  <id_info>
    <org_study_id>NEU - RLZ - 05</org_study_id>
    <nct_id>NCT00202397</nct_id>
  </id_info>
  <brief_title>Effect of Riluzole as a Symptomatic Approach in Patients With Chronic Cerebellar Ataxia</brief_title>
  <official_title>Phase 2 Study of Riluzole Effects on Patients With Chronic Cerebellar Ataxia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>S. Andrea Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>S. Andrea Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cerebellar disorders are often disabling and symptomatic therapies are limited to few options
      that are partially effective. It seems therefore appropriate to search for additional
      approaches.

      Purkinje cells are the sole output of the cerebellar cortex: they project inhibitory signals
      to the deep cerebellar nuclei (DCN), which have a critical role in cerebellar function and
      motor performance. DCN neurons fire spontaneously in the absence of synaptic input from
      Purkinje neurons and modulation of the DCN response by Purkinje input is believed to be
      responsible for coordination of movement. Recent evidences support the notion that an
      increase in DCN excitability may be an important step in the development of cerebellar ataxia
      and point to the underlying molecular mechanisms: the inhibition of small-conductance
      calcium-activated potassium (SK) channels, that causes an increase of the firing frequency in
      DCN, correlates with cerebellar ataxia.

      The rationale of the present project is that SK channel openers, such as riluzole, may have a
      beneficial effect on cerebellar ataxia.

      The researchers propose to perform a pilot study investigating safety and efficacy of
      riluzole, an approved treatment for amyotrophic lateral sclerosis, as a symptomatic approach
      in patients with chronic cerebellar ataxia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Forty patients with chronic cerebellar ataxia will be enrolled in a double-bind, randomized,
      placebo-controlled trial.

      By central randomisation, patients will take 50 mg of riluzole or placebo twice daily for 8
      weeks.

      Electrocardiogram routine laboratory tests and pregnancy tests will be performed before drug
      administration, after 4 weeks of treatment and at the end of the study (after 8 weeks of
      treatment).

      At the same time points the International Cooperative Ataxia Rating Scale (ICARS) for
      pharmacological assessment of the cerebellar syndrome will be administered to the two groups
      (riluzole and placebo) of patients. To guarantee the evaluation of the results in blind
      conditions, the neurologists who will evaluate the ICARS scores will be different from those
      who will deal with randomisation and follow-up of patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The International Cooperative Ataxia Rating Scale (ICARS) total scores and subscores (oculomotor, kinetic, postural, speech), comparing the three time points in the treated versus placebo group</measure>
    <time_frame>pre-treatment, after 4 weeks of treatment and at the end of the study</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Hereditary Ataxia</condition>
  <condition>Multiple Sclerosis</condition>
  <condition>Cerebellar Ataxia</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo bid for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Riluzole, capsule-shaped 50 mg tablets bid for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riluzole</intervention_name>
    <description>capsule-shaped 50 mg tablets bid for 8 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Rilutek ATC Code N07X X02</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>capsule-shaped tablet bid for 8 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with cerebellar degeneration (heredoataxias, sporadic idiopathic ataxia,
             multiple system atrophy type C)

          -  Patients who meet McDonald criteria for probable or definite multiple sclerosis (MS)
             with chronic cerebellar ataxia (not acute cerebellar ataxia due to relapse)

          -  Age between 18 and 80 years

        Exclusion Criteria:

          -  Ataxia due to other diseases

          -  Acute cerebellar ataxia

          -  Use of other drugs for chronic ataxia

          -  Serious concomitant illnesses (cardiac arrhythmias, haematological and hepatic
             diseases)

          -  Pregnancy or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Salvetti, Assoc. Prof</last_name>
    <role>Study Director</role>
    <affiliation>S.Andrea Hospital, University of Rome &quot;La Sapienza&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giovanni Ristori, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Roma La Sapienza</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>S.Andrea Hospital - University of Rome &quot;La Sapienza&quot;</name>
      <address>
        <city>Rome</city>
        <zip>00100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.ospedalesantandrea.it</url>
    <description>sponsor site</description>
  </link>
  <reference>
    <citation>Shakkottai VG, Chou CH, Oddo S, Sailer CA, Knaus HG, Gutman GA, Barish ME, LaFerla FM, Chandy KG. Enhanced neuronal excitability in the absence of neurodegeneration induces cerebellar ataxia. J Clin Invest. 2004 Feb;113(4):582-90.</citation>
    <PMID>14966567</PMID>
  </reference>
  <reference>
    <citation>Aizenman CD, Huang EJ, Linden DJ. Morphological correlates of intrinsic electrical excitability in neurons of the deep cerebellar nuclei. J Neurophysiol. 2003 Apr;89(4):1738-47.</citation>
    <PMID>12686564</PMID>
  </reference>
  <reference>
    <citation>Raman IM, Gustafson AE, Padgett D. Ionic currents and spontaneous firing in neurons isolated from the cerebellar nuclei. J Neurosci. 2000 Dec 15;20(24):9004-16.</citation>
    <PMID>11124976</PMID>
  </reference>
  <reference>
    <citation>Cao YJ, Dreixler JC, Couey JJ, Houamed KM. Modulation of recombinant and native neuronal SK channels by the neuroprotective drug riluzole. Eur J Pharmacol. 2002 Aug 2;449(1-2):47-54.</citation>
    <PMID>12163105</PMID>
  </reference>
  <reference>
    <citation>Doble A. The pharmacology and mechanism of action of riluzole. Neurology. 1996 Dec;47(6 Suppl 4):S233-41. Review.</citation>
    <PMID>8959995</PMID>
  </reference>
  <reference>
    <citation>Trouillas P, Takayanagi T, Hallett M, Currier RD, Subramony SH, Wessel K, Bryer A, Diener HC, Massaquoi S, Gomez CM, Coutinho P, Ben Hamida M, Campanella G, Filla A, Schut L, Timann D, Honnorat J, Nighoghossian N, Manyam B. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci. 1997 Feb 12;145(2):205-11.</citation>
    <PMID>9094050</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>February 10, 2014</last_update_submitted>
  <last_update_submitted_qc>February 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2014</last_update_posted>
  <responsible_party>
    <name_title>Giovanni Ristori</name_title>
    <organization>S.Andrea Hospital - II Faculty of Medicine, &quot;Sapienza&quot; University of Rome</organization>
  </responsible_party>
  <keyword>cerebellar ataxia</keyword>
  <keyword>deep cerebellar nuclei (DCN)</keyword>
  <keyword>small-conductance calcium-activated potassium(SK)channels</keyword>
  <keyword>riluzole</keyword>
  <keyword>Sporadic ataxia</keyword>
  <keyword>Multiple system atrophy type C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Spinocerebellar Degenerations</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riluzole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

